To put this into perspective, the stock is still only really trading at around .009 pre RS. This stock has a lonnnnnngggg way to go to the upside to get back to even close to old highs. Which, if they come through this time on their drug portfolio, should be surpassed easily.
I know that is an IF, but if's and CUBT investment gluts were candy and nuts, oh what a Merry Christmas we would have.
Market Data 
Markets 
